The Caledonian-Record

Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 ...